News - Neurological, Pfizer

Filter

Current filters:

NeurologicalPfizer

Popular Filters

1 to 25 of 58 results

FDA advisory panel ambivalent on NSAID cardiovascular risk

FDA advisory panel ambivalent on NSAID cardiovascular risk

12-02-2014

The US Food and Drug Administration’s joint Arthritis Advisory Committee and Drug Safety and Risk Management…

Anti-Arthritics/RheumaticsBayerNaproxenNeurologicalNorth AmericaPfizerPharmaceuticalUSA

Pfizer’s ALO-02 meets efficacy endpoint in Ph III

Pfizer’s ALO-02 meets efficacy endpoint in Ph III

23-01-2014

US pharma behemoth Pfizer has released top-line results from a Phase III study of ALO-02 (oxycodone HCl…

ALO-02NeurologicalPfizerPharmaceuticalResearch

Nippon Shinyaku and Pfizer conclude exclusive sales promotion on Tramal

30-09-2013

Nippon Shinyaku and Pfizer have concluded an exclusive sales promotion consignment contract in Japan…

Asia-PacificLicensingMarkets & MarketingNeurologicalNippon ShinyakuPfizerPharmaceuticalTramadol Hydrochloride

Karo Bio gets first milestone in Pfizer collaboration

06-09-2013

Under its collaboration with US pharma behemoth Pfizer (NYSE: PFE), Sweden's Karo Bio (STO: KARO) says…

Anti-Arthritics/RheumaticsDermatologicalsFinancialKaro BioLicensingNeurologicalPfizerPharmaceuticalResearch

Abcam in deal with Pfizer to supply compounds to researchers

12-06-2013

UK-based Abcam (AIM: ABC), a producer and distributor of protein research tools, has entered into a license…

AbcamCardio-vascularLicensingNeurologicalOncologyPfizerPharmaceuticalResearch

Lilly drops enzastaurin development; Remoxy future viewed by Pfizer and partners

10-05-2013

US drug major Eli Lilly (NYSE: LLY) revealed that Phase III clinical trial results from enzastaurin's…

DurectEli LillyenzastaurinNeurologicalOncologyPain TherapeuticsPfizerPharmaceuticalRegulationRemoxyResearch

New York parents charge Pfizer for concealing true risks of birth defects linked to Zoloft

07-05-2013

A law suit against pharmaceutical giant Pfizer (NYSE: PFE), for the permanent and devastating injuries…

LegalMarkets & MarketingNeurologicalNorth AmericaPfizerPharmaceuticalZoloft

GSK returns IPX066 rights to Impax; Merck & Co and Pfizer link up on diabetes drug

30-04-2013

US biotech firm Impax Laboratories (Nasdaq: IPXL) saw its shares fall 2% to $17.32 in premarket trading,…

BiotechnologyDiabetesertugliflozinGlaxoSmithKlineImpax LaboratoriesIPX066LicensingMerck & CoNeurologicalPfizerPharmaceuticalResearch

Appeals Court rules against EMD Serono over Rebif deal with Pfizer

16-04-2013

Germany's Merck KGaA (MRK: DE) says that a Pennsylvania appeals court has ruled against Merck in deciding…

BiotechnologyEMD SeronoLegalMarkets & MarketingMerck KGaANeurologicalNorth AmericaPfizerPharmaceuticalRebif

Ranbaxy in deal with Alembic to market bioequivalent Pristiq in USA

05-03-2013

The US subsidiary of India's largest drugmaker, Ranbaxy Laboratories (AB: BO), which is majority owned…

Alembic PharmaceuticalsDaiichi SankyoGenericsLicensingMarkets & MarketingNeurologicalNorth AmericaPatentsPfizerPristiqRanbaxy Laboratories

Pfizer's Lyrica equals levetiracetam in patients with partial onset seizures

22-02-2013

Global pharma behemoth Pfizer (NYSE: PFE) has announced top-line results from a Phase III study showing…

LyricaNeurologicalPfizerPharmaceuticalResearch

Research results for Pfizer's Chantix, Pristiq and Toviaz

27-01-2013

Global drugs behemoth Pfizer (NYSE: PFE) last week released a batch of new clinical trial data relating…

ChantixGenito-urinaryNeurologicalPfizerPharmaceuticalPristiqResearchToviaz

Pfizer's Quillivant XR oral suspension now available in USA; GlaxoSmithKline files BLA for albiglutide

15-01-2013

Confirming expectations announced when Pfizer (NYSE: PFE) revealed its $680 million acquisition of NextWave…

albiglutideDiabetesGlaxoSmithKlineMarkets & MarketingNeurologicalNorth AmericaPfizerPharmaceuticalQuillivantRegulation

Repligen in $70 million deal with Pfizer for SMA program

04-01-2013

USA-based Repligen (Nasdaq: RGEN) saw its share jump 5.6% to $6.63, after the company revealed it has…

BiotechnologyLicensingNeurologicalPfizerPharmaceuticalRare diseasesRepligenRG3039

US FDA approves Merck KGaA's Rebif Rebidose

04-01-2013

German drug major Merck KGaA's (MRK: DE) US subsidiary EMD Serono and pharma behemoth Pfizer (NYSE: PFE)…

BiotechnologyEMD SeronoMerck KGaANeurologicalNorth AmericaPfizerPharmaceuticalRebifRegulation

Japanese approvals for Novo's Ryzodeg, UCB/Otsuka's Neupro and B-MS/Pfizer's Eliquis

27-12-2012

Danish insulin giant Novo Nordisk (NOVN: NV) revealed on December 15 that the Japanese Ministry of Health,…

Asia-PacificBristol-Myers SquibbCardio-vascularDiabetesEliquisNeuproNeurologicalNovo NordiskOtsukaPfizerPharmaceuticalRegulationRyzodegUCB

Insights on the US Alzheimer's disease market

03-12-2012

The treatment of Alzheimer's disease (AD) offers a compelling commercial opportunity for the pharmaceutical…

AriceptEisaiExelonForest LaboratoriesGenericsMarkets & MarketingNamendaNeurologicalNorth AmericaNovartisPfizerPharmaceutical

Pfizer's Lyrica misses primary endpoint in seizure frequency trial; positive in fibromyalgia

20-11-2012

US pharma behemoth Pfizer (NYSE: PFE) revealed disappointing top-line results of a double-blind, placebo-controlled,…

LyricaNeurologicalPfizerPharmaceuticalResearch

1 to 25 of 58 results

Back to top